Henry Schein, Inc. (NASDAQ:HSIC) Position Trimmed by Entropy Technologies LP

Entropy Technologies LP lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,345 shares of the company’s stock after selling 1,751 shares during the period. Entropy Technologies LP’s holdings in Henry Schein were worth $1,408,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of HSIC. ING Groep NV acquired a new position in shares of Henry Schein in the 3rd quarter worth $63,226,000. Holocene Advisors LP acquired a new position in shares of Henry Schein in the 3rd quarter valued at $58,319,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Henry Schein in the 3rd quarter valued at $43,740,000. Southpoint Capital Advisors LP increased its stake in Henry Schein by 30.0% in the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after purchasing an additional 600,000 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after buying an additional 558,689 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $78.90 on Tuesday. The firm has a market cap of $9.84 billion, a P/E ratio of 32.47, a PEG ratio of 2.21 and a beta of 0.91. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a fifty-two week low of $63.67 and a fifty-two week high of $82.63. The stock’s 50-day moving average is $73.75 and its two-hundred day moving average is $71.86.

Insider Buying and Selling

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at $6,577,950. The trade was a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.14% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HSIC has been the subject of several recent analyst reports. Barrington Research raised their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, January 30th. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Mizuho started coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price on the stock. Jefferies Financial Group raised their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.